Cilostazol: clinical trials recruiting now
4
Recruiting trials
6
Conditions studied
1
US states with sites
3
Countries
FDA drug label
- FDA-approved
- Yes. Cilostazol appears in the FDA drug-label database. Marketed as cilostazol.
- Drug class
- Phosphodiesterase 3 Inhibitor (FDA established pharmacologic class)
- Mechanism of action
- Phosphodiesterase 3 Inhibitors (as stated on the FDA label)
- Boxed warning
- The FDA label for Cilostazol carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol is a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance ( 1 )
Phase breakdown
Phase 1 2
Phase 2 2
Phase 4 2
Conditions being studied
| Condition | Trials |
|---|---|
| Atherosclerosis | 2 |
| Type 2 Diabetes | 2 |
| Fatty Liver | 1 |
| Multiple Sclerosis | 1 |
| NASH | 1 |
| Type 2 Diabetes Mellitus (T2DM) | 1 |
Recruiting trials involving Cilostazol
- Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
- Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
- Clopidogrel Versus Cilostazol on Vessels
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Common questions
Is Cilostazol FDA-approved?
Yes, marketed as cilostazol. Its FDA label carries a boxed warning.
How many recruiting trials involve Cilostazol?
4 recruiting trials across 6 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.